[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc has announced the purchase of 1,561,229 ordinary shares under the second tranche of its share buyback programme and intends to hold these shares as treasury stock. After settlement, the company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, with 45,962,012 held as treasury shares, leaving 8,906,391,636 voting shares. The announcement confirms completion of the final tranche of the buyback programme launched 28 March 2025. Since the start of the year, including shares acquired from Pfizer, Haleon repurchased 175,806,525 shares: 131,372,271 were cancelled and 44,434,254 remain as treasury shares. A full trade breakdown is available via the provided link.

Positive

• Buyback programme completed: Final tranche settled, concluding the programme announced 28 March 2025
• Material repurchases year-to-date: 175,806,525 shares repurchased, reducing outstanding shares
• Cancellation and treasury split disclosed: 131,372,271 shares cancelled and 44,434,254 held in treasury
• Clear post-transaction counts: Registered capital and voting share totals provided for shareholder reference

Negative

• None.

Insights

Financial Analyst

TL;DR: Buyback completion reduces outstanding float and signals capital return to shareholders.

The company completed its announced buyback programme, repurchasing 175.8 million shares year-to-date, of which 131.4 million were cancelled and 44.4 million are treasury shares. This reduces the shares outstanding and concentrates ownership among remaining holders, which can be accretive to metrics like EPS on a per-share basis absent offsetting operational effects. The filing provides precise post-transaction share counts, enabling investors to recalculate ownership thresholds and notification requirements under disclosure rules. No forward-looking statements or financial impacts beyond share movements are provided in the release.

Corporate Governance Expert

TL;DR: Completion of the programme clarifies share capital structure and regulatory disclosure triggers.

The announcement confirms settlement details and that purchased shares will be held as treasury stock, with a proportion already cancelled. The updated registered capital and voting-share count are clearly stated, which is important for shareholders monitoring voting power and notification thresholds under FCA rules. The company also supplies a trade breakdown link to satisfy market-abuse disclosure requirements. There are no governance changes or executive actions disclosed in this release.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	02 October 2025 - “Transaction in Own Shares & Buyback Update”

99.1

Haleon plc: Transaction in own shares and update on the Buyback Programme

02 October 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,561,229 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	01 October 2025	01 October 2025	01 October 2025
Number of Shares purchased:	1,561,229	-	-
Highest price paid per Share (p):	337.5000	-	-
Lowest price paid per Share (p):	331.9000	-	-
Volume weighted average price paid per Share (p):	335.0704	-	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 45,962,012 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,906,391,636 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/7242B_1-2025-10-1.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Completion of the Buyback Programme

Following the above transaction, Haleon has completed the final tranche of the Buyback Programme announced on 28 March 2025.

Since the start of the year, including the Shares purchased from Pfizer, the Company has repurchased 175,806,525 Shares, of which 131,372,271 were cancelled and 44,434,254 were held as treasury shares.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: October 02, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What share buyback activity did Haleon (HLN) report on October 2, 2025?

Haleon reported purchasing 1,561,229 ordinary shares under the second tranche of its buyback programme and intends to hold them as treasury shares.

How many Haleon shares have been repurchased year-to-date including the Pfizer purchase?

The company repurchased 175,806,525 shares year-to-date; 131,372,271 were cancelled and 44,434,254 are held as treasury shares.

What are Haleon's post-transaction share counts?

Registered share capital is 8,952,353,648 ordinary shares; 45,962,012 are treasury shares, leaving 8,906,391,636 voting shares.

Where can I find a full breakdown of the individual trades?

A full trade breakdown is provided via the link in the announcement: http://www.rns-pdf.londonstockexchange.com/rns/7242B_1-2025-10-1.pdf and on Haleon's investor website.

Does the announcement include forward-looking financial guidance?

No. The announcement only discloses share repurchase details, post-transaction share counts and where to find the trade breakdown.